SCHEMBL2385207

SCHEMBL2385207

NOCc1cccc(-c2ccccn2)n1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.57
LMNA P02545 3/20 0.57
CCR1 P32246 3/20 0.57
CCR5 P51681 3/20 0.57
CCR8 P51685 3/20 0.57
ALOX15 P16050 3/20 0.57
L3MBTL1 Q9Y468 3/20 0.57
SMN1; SMN2 Q16637 3/20 0.57
TP53 P04637 3/20 0.57
HTT P42858 2/20 0.57
TDP1 Q9NUW8 2/20 0.57
ALPL P05186 1/20 0.57
HSP90AA1 P07900 1/20 0.57
ALPI P09923 1/20 0.57
ALPG P10696 1/20 0.57
MAPK1 P28482 1/20 0.57
CYP1A2 P05177 1/20 0.48
POLB P06746 1/20 0.48
METAP1 P53582 1/20 0.48
BLM P54132 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5013989 0.84 KCNH2 (0.39) KDM4ELMNACCR1CCR5CCR8
SCHEMBL5012722 0.82 GABRA1 (0.39) KDM4ELMNACCR1CCR5CCR8
SCHEMBL5016048 0.81 ASIC3 (0.44) KDM4ELMNACCR1CCR5CCR8
SCHEMBL15217633 0.80 KDM4E (0.63) KDM4ELMNACCR1CCR5CCR8
SCHEMBL1411802 0.79
SCHEMBL29614705 0.79
SCHEMBL14075009 0.79 KDM4E (0.52) KDM4ELMNACCR1CCR5CCR8
SCHEMBL5013990 0.79 HIF1A (0.36) KDM4ELMNACCR1CCR5CCR8
SCHEMBL4344143 0.79 ASIC3 (0.46) KDM4EL3MBTL1TDP1ALDH1A1HPGD
SCHEMBL16588053 0.79 KCNH2 (0.36) CCR1CCR8KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293715-B2 10a-Azalide compound crosslinked at 10a- and 12-positions TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-10-23 US disclosed
US-20110237784-A1 10A-AZALIDE COMPOUND CROSSLINKED AT 10A- AND 12-POSITIONS TAISHO PHARMACEUTICAL CO., LTD. (JP) 2011-09-29 US disclosed
EP-2177526-A1 10A-AZALIDE COMPOUND CROSSLINKED AT POSITION-10A AND POSITION-12 Taisho Pharmaceutical Co. Ltd. (JP) 2010-04-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237784-A1 10A-AZALIDE COMPOUND CROSSLINKED AT 10A- AND 12-POSITIONS DCLRE1A, AZI2, CHD9 KDM4E 64/4885LMNA 1834/4885CCR1 2941/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.